S. 2658In markupJobs & the economy
Bill would force drug firms to match FDA and patent office filings
Data as of July 16, 2026
Drug companies would have to certify that FDA and patent office filings match, or face penalties.40-second read · 4 questions answered below
Decoded
What does this do?
This bill requires drug companies to certify that information given to the FDA about a drug's makeup, testing, and manufacturing matches what they tell the USPTO for patent purposes. Companies would also share relevant technical information between the two agencies. This aims to prevent "patent thicketing," where inconsistent information is used to obtain extra patents extending drug control.
Who does it affect?
Pharmaceutical and biotech companies making brand-name drugs and biologics, and their legal and regulatory teams, are directly affected. Consumers and generic/biosimilar competitors could be indirectly affected.
Why does it matter?
Companies that fail to make required disclosures or certifications could face FDA enforcement penalties. Generic or biosimilar companies sued for patent infringement could use a patent holder's non-disclosure as a legal defense.
Where does it stand?
- Introduced
- Senate committee — You are here
- Senate vote
- House
- President's desk
Right now: a Senate committee is reviewing it. If the House changes it, it goes back to the Senate before reaching the President.
AI-drafted summary. Verify it against the official text before you act on it.
Three steps: where you stand, your script, the call.
Make the callSee how a call works
Official title
Medication Affordability and Patent Integrity Act
- Introduced:
- August 1, 2025
- Latest action:
- June 17, 2026
Committee on Health, Education, Labor, and Pensions. Ordered to be reported with an amendment in the nature of a substitute favorably.
Read the official bill on Congress.govMake the call
Three steps: where you stand, your script, the call.